Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05243550 · OUTCOME

Complete Response Rate (CRR)

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer · Source last updated 2026-05-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
3 months

What was measured

CRR is defined as the percentage of patients who achieved a complete response (CR) at the 3-month Visit. A patient was considered a CR if there was no detectable disease in the bladder based on visual observation (white light cystoscopy), biopsy of remaining lesions (if applicable), and voiding urine cytology.

Analysis population: All patients who received any dose of UGN-102.

Groups in this outcome

UGN-102

6 once-weekly intravesical instillations of UGN-102 (75 mg mitomycin).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
UGN-102240

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
UGN-10276.7Not reported70.881.9Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        70.8
        upper Limit
        81.9
        value
        76.7
denoms
  1. counts
    1. group Id
      OG000
      value
      240
    units
    Participants
description
CRR is defined as the percentage of patients who achieved a complete response (CR) at the 3-month Visit. A patient was considered a CR if there was no detectable disease in the bladder based on visual observation (white light cystoscopy), biopsy of remaining lesions (if applicable), and voiding urine cytology.
dispersion Type
95% Confidence Interval
groups
  1. description
    6 once-weekly intravesical instillations of UGN-102 (75 mg mitomycin).
    id
    OG000
    title
    UGN-102
param Type
NUMBER
population Description
All patients who received any dose of UGN-102.
reporting Status
POSTED
time Frame
3 months
title
Complete Response Rate (CRR)
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice